Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 67

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 67
---
The
following discussion and analysis should be read in conjunction with the Condensed Financial Statements and Notes thereto included elsewhere
in this Quarterly Report. This discussion contains certain forward-looking statements that involve risks and uncertainties. The Company’s
actual results and the timing of certain events could differ materially from those discussed in these forward-looking statements as a
result of certain factors, including, but not limited to, those set forth herein and elsewhere in this Quarterly Report and in the Company’s
other filings with the SEC. See “Cautionary Note Regarding Forward Looking Statements” below.

As
used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, unless otherwise indicated,
the terms “the Company”, “we”, “us”, “our” and similar terminology refer to Telomir Pharmaceuticals,
Inc.

Telomir
Pharmaceuticals (NASDAQ:TELO) is a pre-clinical stage biotechnology company developing therapies designed to target the root epigenetic
mechanisms underlying cancer, aging, and degenerative disease. The Company’s lead candidate, Telomir-1, has demonstrated activity
in preclinical studies involving modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression,
cellular function, and genomic stability. Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps,
maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal
ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder
that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related
Macular Degeneration (AMD), as well as Type 2 diabetes, cancer, and Alzheimer’s disease.

Telomir-1
Program Overview

Telomir-1
is an investigational, orally administered small-molecule candidate designed to target fundamental biological processes believed to contribute
to aging, cancer, metabolic, and other age-related diseases. The compound acts as a regulator of essential metal ions and an epigenetic
modulator, influencing cellular pathways that govern oxidative stress, mitochondrial function, DNA methylation, and telomere maintenance—core
mechanisms broadly implicated in degenerative, inflammatory, metabolic, and oncologic conditions.

Epigenetics
refers to the way cells control gene activity without altering the underlying